# The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)

> **NCT06699836** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **CytoDyn, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** 350 mg leronlimab
- **DRUG:** 700 mg leronlimab

## Key facts

- **NCT ID:** NCT06699836
- **Lead sponsor:** CytoDyn, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2028-01
- **Final completion:** 2028-03
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06699836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06699836, "The Phase-2 CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen Trial (CLOVER)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06699836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*